

Title (en)
MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS
IN THE TREATMENT OF HIV/AIDS

Title (de)
MITTEL UND VERFAHREN ZUR ÜBERWACHUNG EINER ANTIRETROVIRALEN PROTEASEINHIBITORTHERAPIE UND ALS RICHTSCHNUR
FÜR THERAPEUTISCHE ENTSCHEIDUNGEN BEI DER BEHANDLUNG VON HIV/AIDS

Title (fr)
DISPOSITIF ET METHODES DE SURVEILLANCE D'UNE THERAPIE ANTIRETROVIRALE INHIBITRICE DE LA PROTEASE ET
DETERMINATION DE DECISIONS THERAPEUTIQUES DANS LE TRAITEMENT DU VIH/SIDA

Publication
EP 1407042 A4 20060222 (EN)

Application
EP 02744311 A 20020604

Priority
• US 0218684 W 20020604
• US 87447201 A 20010604
• US 0201682 W 20020118

Abstract (en)
[origin: WO02099387A2] This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.

IPC 1-7
C12Q 1/18; **C12Q 1/68**; **C12Q 1/70**; **G01N 33/569**

IPC 8 full level
C07K 14/16 (2006.01); **C12Q 1/37** (2006.01); **C12Q 1/70** (2006.01); **G01N 33/569** (2006.01)

CPC (source: EP)
C07K 14/005 (2013.01); **C12Q 1/37** (2013.01); **C12Q 1/703** (2013.01); **C12N 2740/16043** (2013.01); **C12N 2740/16222** (2013.01);
G01N 2500/10 (2013.01)

Citation (search report)
• [X] WO 0078996 A1 20001228 - VIROLOGIC INC [US]
• [DA] PATICK A K ET AL: "Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 42, no. 10, October 1998 (1998-10-01), pages 2637 - 2644, XP002978189, ISSN: 0066-4804
• [A] CONDRA J ET AL: "Genetic correlation of in vivo viral isolates to indinavir, a human immunodeficiency type 1 protease inhibitor", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 12, December 1996 (1996-12-01), pages 8270 - 76, XP002150116, ISSN: 0022-538X
• [A] TISDALE MARGARET ET AL: "Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies: A review", CLINICAL DRUG INVESTIGATION, vol. 20, no. 4, October 2000 (2000-10-01), pages 267 - 285, XP008046792, ISSN: 1173-2563
• [X] TEBAS PABLO ET AL: "Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir", AIDS (HAGERSTOWN), vol. 13, no. 2, 4 February 1999 (1999-02-04), pages F23 - F28, XP002327593, ISSN: 0269-9370
• [DA] SHAFER R W ET AL: "Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 1, 1 January 1999 (1999-01-01), pages 348 - 352, XP002202303, ISSN: 0305-1048
• See references of WO 02099387A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 02099387 A2 20021212; **WO 02099387 A3 20030424**; EP 1407042 A2 20040414; EP 1407042 A4 20060222

DOCDB simple family (application)
US 0218684 W 20020604; EP 02744311 A 20020604